Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate

Medical Oncology

Volumn 21, Issue 4, 2004, Pages 349-358

  Hardling, Mats ^a   Wei, Yuan ^a   Palmqvist, Lars ^a   Swolin, Birgitta ^a   Stockelberg, Dick ^a   Gustavsson, Bengt ^b   Ekeland Sjöberg, Kerstin ^a   Wadenvik, Hans ^a   Ricksten, Anne ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Novartis AB ^*  (Sweden)

Author keywords

Chronic myelogenous leukemia; Cytogenetics; Imatinib mesylate; PCR; STI571

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; BCR ABL GENE; BONE MARROW BIOPSY; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FUSION GENE; GENE; GENE TARGETING; HUMAN; MALE; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; FEMALE; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 11244331317     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:4:349     Document Type: Article

References (34)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247(4946):1079-1082.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247(4944): 824-830.
3. Mahon FX, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20(1):214-220.
4. Bonifazi F, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98(10):3074-3081.
5. O'Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994-1004.
6. Kantarjian H, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9):645-652.
7. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998; 16(4):1526-1531.
8. Hochhaus A, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95(1):62-66.
9. Hughes TP, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349(15):1423-1432.
10. An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S. Kager: Basel, 1995.
11. Druker BJ, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038-1042.
12. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314(17):1065-1069.
13. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000; 46(7):913-920.
14. Deininger MW. Cytogenetic studies in patients on imatinib. Semin Hematol 2003; 40(2 Suppl 3):50-55.
15. Medina J, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98(9):1905-1911.
16. Hochhaus A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87(4):1549-1555.
17. Lin F, Goldman JM, Cross NC. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994; 86(3):683-685.
18. Tchirkov A, et al. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy. Br J Haematol 1998; 101(3):552-557.
19. Hochhaus A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87(4):1549-1555.
20. Lin F, van Rhee F, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87(10):4473-4478.
21. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341 (8840):275-276.
22. Olavarria E, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97(6): 1560-1565.
23. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107(3):587-599.
24. Preudhomme C, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia 1999; 13(6):957-964.
25. Zanella I, Rossi G, Finazzi D, Capucci A, Albertini A, Cariani E. Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia. Haematologica 2001; 86(3):318-319.
26. Amabile M, et al. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001; 86(3):252-259.
27. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13(9): 1383-1389.
28. Elmaagacli AH, et al. Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol 2001; 113(4):1072-1075.
29. Mensink E, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102(3):768-774.
30. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120(6):990-999.
31. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118(3):771-777.
32. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003; 40(2 Suppl 3):98-103.
33. Zhu G, et al. Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH. Biochem Biophys Res Commun 2001; 281(4):951-956.
34. Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17:2474-2486.